BioMarin: Stable Durable Bleed Control for ROCTAVIAN in Phase 3 Hemophilia Gene Therapy Study

 Mean Annualized Bleed Rate Reduced by 80% from Baseline and Factor VIII Usage Reduced by 94% in Year 3 Compared to Baseline

  - 92% of Patients off Prophylaxis at the End of Year 3

- First Outcomes-Based Agreement (OBA) Recently Signed in Germany; Additional Agreements Expected to be Signed in Coming Weeks

https://www.marketscreener.com/quote/stock/BIOMARIN-PHARMACEUTICAL-I-8587/news/BioMarin-Announces-Stable-and-Durable-Annualized-Bleed-Control-for-ROCTAVIAN-trade-in-Largest-Phase-42688097/